Full-Time

Senior Manager Site Self Inspection Lead

Confirmed live in the last 24 hours

Viatris

Viatris

10,001+ employees

Global pharmaceutical company providing medicines

No salary listed

Senior, Expert

San Antonio, TX, USA

In Person

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • Bachelor's degree in Science, Engineering, or related technical discipline from a four-year college or university is required. MBA is a plus.
  • Minimum 10 years’ experience in a GXP setting, extending across a range of functions inclusive of Quality Assurance.
  • Extensive understanding of pharmaceutical cGMP and global government regulations, including Viatris policies, procedures and associated documents (corporate, regional, site), local regulations, US FDA, WHO EMA, ICH and ISO 9001 (as applicable to the site) and a comprehensive understanding of how areas collectively integrate and contribute to achieving the goals of the business.
  • Possess an in-depth knowledge of quality system requirements; including a demonstrated ability to evaluate and apply global GMP’s to support evaluation and enhancement to site systems and processes. Requires specialized depth and/or breadth of expertise in quality systems.
  • Demonstrated personal leadership, accountability, and organizational skills with proven ability to operate independently with minimal supervision.
  • Comprehensive and demonstrated written and verbal communication skills are required. May be required to communicate difficult concepts and negotiate with others to adopt a different point of view.
  • Demonstrated ability to negotiate and collaborate with individuals and groups at multiple levels across the organization including senior leadership of various functional lines across Viatris.
  • Travel Expectation: Some travel expected. Potential for travel up to 20% of time.
Responsibilities
  • Creation and tracking of the site self-inspection plan, inclusive of self-inspection scheduling and development of self-inspection agenda.
  • Liaising with Site Leadership and Global Operations Auditing to gain alignment on self-inspection plan schedule and scope.
  • Leading and participating in site self-inspections. Ensuring each self-inspection is appropriately recorded and communicated. Performing frequent unplanned and planned walk-through inspections of the facility.
  • Evaluation and tracking of CAPA items from self-inspections and providing guidance to site functions to ensure robust, holistic actions are developed. Ensuring that CAPAs are verified for effectiveness.
  • Prepare annual trend reports for site self-inspection data and collaborate across Viatris to identify Global and/or regional opportunities. Facilitate bi-monthly reviews with site and global personnel to discuss site learnings and opportunities.
  • Responsible for Site Audit Module and associated processes and procedures.
  • Support overall site Inspection Readiness Plan, participating as required in site Board of Health inspections.
  • Participate in Global Operations Audits of Viatris facilities.
  • Perform external audits of third-party suppliers as aligned with site and GOA requirements.
  • Participate in global audit training and disseminate relevant detail to site teams. Provide training and coaching as required to broader site self-inspection team.
  • Support any of the site quality culture initiatives.
  • Within area of responsibility, understand and comply with all safety, environmental and quality practices and procedures as outlined in organizational/departmental guidelines and SOPs as well as applicable federal, state and local regulations.
  • Perform other duties as required by management.
Desired Qualifications
  • MBA is a plus.

Viatris is a global pharmaceutical company that provides access to a wide range of medicines, including branded and generic drugs, complex generics, and biosimilars. The company operates by leveraging its extensive global commercial infrastructure and supply chain to deliver high-quality medications to patients in over 165 countries. Viatris generates revenue through the sale of its pharmaceutical products, focusing on key therapeutic areas such as cardiovascular health, infectious diseases, immunology, and oncology. What sets Viatris apart from its competitors is its commitment to addressing public health challenges, particularly the increasing prevalence of non-communicable diseases. The company's goal is to achieve organic growth through its existing product offerings while also pursuing strategic partnerships and acquisitions to expand its reach and impact in the healthcare sector.

Company Size

10,001+

Company Stage

IPO

Headquarters

Canonsburg, Pennsylvania

Founded

1961

Simplify Jobs

Simplify's Take

What believers are saying

  • Viatris benefits from the growing biosimilars market, projected to grow at 24.7% CAGR.
  • The Asia-Pacific pharmaceutical market's growth offers expansion opportunities for Viatris.
  • Increased demand for cardiovascular drugs aligns with Viatris's key therapeutic areas.

What critics are saying

  • Increased competition in biosimilars could impact Viatris's market share and pricing power.
  • Patent litigation may lead to financial liabilities or loss of market exclusivity.
  • Viatris's significant debt load could limit financial flexibility and growth investments.

What makes Viatris unique

  • Viatris combines generics and branded drugs to address global healthcare needs holistically.
  • The company leverages a unique global supply chain to deliver medicines to 165 countries.
  • Viatris's diverse portfolio includes branded drugs, generics, complex generics, and biosimilars.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Paid Holidays

Company News

The Indian Express
Jun 24th, 2025
Biocon's $3.3B Viatris Acquisition Impact

Biocon's acquisition of Viatris for $3.3 billion marks a potential turning point for the company, which has seen muted growth. Despite revenue growth, concerns about debt, equity dilution, and valuation persist. Biocon's business now includes biosimilars, contract research, and generics. The company plans to raise ₹4,500 crore through a Qualified Institutional Placement to reduce its ₹17,756 crore debt. A potential merger with Biocon Biologics Ltd could unlock further value.

PharmiWeb
May 7th, 2025
Viatris Announces Quarterly Dividend

PITTSBURGH, May 7, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that on May 5, 2025, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on June 16, 2025, to shareholders of record as of the close of business on May 23, 2025.About ViatrisViatris Inc. (Nasdaq: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale, currently supplying high-quality medicines to approximately 1 billion patients around the world annually and touching all of life's moments, from birth to the end of life, acute conditions to chronic diseases. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges, access takes on deep meaning at Viatris

PR Newswire
Mar 28th, 2025
Viatris To Report First Quarter 2025 Financial Results On May 8, 2025

PITTSBURGH, March 28, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will report first quarter 2025 financial results on Thursday, May 8, 2025. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results.Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website.About ViatrisViatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally

PR Newswire
Mar 5th, 2025
Viatris To Present At The Barclays 27Th Annual Global Healthcare Conference

PITTSBURGH, March 5, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, will present at the Barclays 27th Annual Global Healthcare Conference in Miami Beach, FL on Tuesday, March 11, 2025. The company's fireside chat will begin at 2 p.m. ET.A live webcast of the event at can be found at investor.viatris.com. An archived version of the presentation will be available following the live event and can be accessed at the same location for a limited time.About ViatrisViatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally